[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Stoke Therapeutics director Edward M. Kaye sold shares to satisfy tax withholding tied to restricted stock unit vesting. The Form 4 reports an issuer-mandated sale of 12,126 shares of common stock on 08/18/2025 at a weighted average price of $18.238 per share, with individual sale prices ranging from $18.00 to $18.50. After the sale, Dr. Kaye beneficially owned 153,470 shares as a direct owner. The filing indicates the transaction was to cover tax withholding on settled restricted stock units and was signed by an attorney-in-fact on 08/20/2025.

Positive

• Transaction clearly disclosed with date, share count, weighted average price and price range
• Sale explicitly tied to tax withholding on RSU vesting, indicating a non-discretionary issuer-mandated transaction
• Post-transaction beneficial ownership provided (153,470 shares), aiding transparency

Negative

• Director's holdings decreased by 12,126 shares due to the sale
• Filing lacks company-wide context such as total shares outstanding, so materiality cannot be assessed from this form alone

Insights

Securities Analyst

TL;DR: Routine insider sale to cover RSU tax withholding; not an indicator of performance change.

The Form 4 documents a non-discretionary, issuer-mandated sale of 12,126 shares by a director to satisfy tax obligations from RSU settlement. Because the sale is explicitly tied to tax withholding rather than discretionary divestment, it carries limited informational content about the director's view on company prospects. The weighted average sale price of $18.238 and disclosed price range provide transparency on execution. Investors should note the post-transaction direct beneficial ownership figure of 153,470 shares for context, though materiality depends on total outstanding shares which is not provided in this filing.

Corporate Governance Expert

TL;DR: Filing follows expected compliance practices for RSU withholding sales; disclosure appears complete for this event.

The disclosure identifies the reporting person as a director and classifies the sale as an issuer-mandated transaction to satisfy tax withholding obligations arising from RSU vesting. The form includes transaction date, number of shares sold, weighted average price and price range, and resulting beneficial ownership, meeting typical Section 16 reporting standards. The presence of an attorney-in-fact signature is noted; the filing does not indicate any other insider transactions or arrangements. Absent other context, this is a routine compliance disclosure rather than a governance red flag.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Edward M. MD

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2025		S(1)		12,126	D	$18.238(2)	153,470	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.50 per share, inclusive.

	/s/ Jonathan Allan, Attorney-in-Fact	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Stoke Therapeutics (STOK) insider Edward M. Kaye do on 08/18/2025?

He sold 12,126 shares of common stock on 08/18/2025 in an issuer-mandated sale to satisfy tax withholding related to RSU vesting.

At what price were the STOK shares sold by the director?

The filing reports a weighted average price of $18.238 per share, with sale prices ranging from $18.00 to $18.50.

How many STOK shares did Edward M. Kaye own after the sale?

After the reported transaction, he beneficially owned 153,470 shares as a direct owner.

Why were the STOK shares sold according to the Form 4?

The Form 4 states the sale was an issuer-mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

Who signed the Form 4 for this transaction?

The document is signed by Jonathan Allan, Attorney-in-Fact, with a signature date of 08/20/2025.